IV ibandronic acid an upcoming DIVA on the osteoporosis stage

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1495, 2005-01, pp. : 7-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Roche and GlaxoSmithKline have launched IV ibandronic acid [Bonviva] for postmenopausal osteoporosis in the UK

Inpharma, Vol. 1, Iss. 1536, 2006-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

MOTION supports ibandronic acid in postmenopausal osteoporosis

Inpharma, Vol. 1, Iss. 1611, 2007-01 ,pp. : 17-18

Adis International

Access to resources Recommend Favorite

Osteoporosis treatment: why ibandronic acid?

By Rossini Maurizio Orsolini Giovanni Adami Silvano Kunnathully Vidya Gatti Davide

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1371-1381

Informa Healthcare

Access to resources Recommend Favorite

The incidence of adverse events (AEs) appears to be higher with IV zoledronic acid than with oral ibandronic acid

Inpharma, Vol. 1, Iss. 1516, 2005-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Ibandronic acid: Musculoskeletal pain: case report

Reactions Weekly, Vol. 1, Iss. 1218, 2008-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite